-+ 0.00%
-+ 0.00%
-+ 0.00%

Corcept To Present Late-Breaking Data From Pivotal Phase 3 ROSELLA Trial Of Relacorilant In Platinum-Resistant Ovarian Cancer At ASCO 2025

Benzinga·04/23/2025 15:35:04
Listen to the news

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data will be presented in a late-breaking oral presentation on Monday, June 2, 2025.

  • Title: ROSELLA: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer​ (GOG-3073, ENGOT-ov72)
  • Oral Abstract Session – Gynecologic Cancer
  • June 2, 2025, 8:00 AM – 11:00 AM CDT
  • Abstract Number: LBA5507

The ROSELLA trial is being conducted in collaboration with The GOG Foundation, Inc. (GOG-F), the European Network of Gynaecological Oncological Trial groups (ENGOT), the Asia-Pacific Gynecologic Oncology Trials Group (APGOT), the Latin American Cooperative Oncology Group (LACOG) and the Australia New Zealand Gynaecological Oncology Group (ANZGOG).